Status:
TERMINATED
The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases
Lead Sponsor:
Semmelweis University
Conditions:
Chronic Lymphoid Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Recent data have shown that the inadequate vitamin D status plays a role in the manifestation of the haematologic tumors and serum vitamin D level has a prognostic role also as it determines the tumor...
Eligibility Criteria
Inclusion
- at least 18 years old male or female
- chronic lymphoid leukaemia, any Rai stage
- 25-OH-Vitamin-D3 level between 10 and 30 ng/mL
Exclusion
- serum calcium \> 2,60 mmol/l
- 24 hour calcium urine excretion \> 0,1 mmol/kg/day
- serum phosphate \> 1,45 mmol/l
- eGFR \< 30 ml/min/1,73m2
- nephrolithiasis
- receiving parenteral vitamin-D3 in past 6 months
- activated vitamin-D3 treatment
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2017
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01518959
Start Date
January 1 2012
End Date
January 1 2017
Last Update
July 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Semmelweis University - 1st Departement of Internal Medicine
Budapest, Hungary, 1083